PROUD-PV

1. 01

   Molecular response is gaining clinical meaning, but its role in changing treatment remains contested

   Sample finding · free

   An X thread asked whether molecular response during ropeginterferon treatment, including a fall in JAK2 allele burden, translates into a change in the course of PV.

   Source: X thread, 2023-12-10 · paraphrased; the full report links the source

2. 02

   Earlier cytoreduction in low-risk PV attracts support, but deferral remains an active-management position

3. 03

   The favorable reading is time-dependent and must remain beside the early endpoint and extension qualifications

   Sample finding · free

   A podcast speaker asked whether an abstract concerned the original PROUD-PV study, its CONTINUATION-PV extension or a particular component of longer-term follow-up.

   Source: podcast, 2024-09-13 · paraphrased; the full report links the source

4. 04

   Improved tolerability does not remove psychiatric, autoimmune or organ-specific selection and stopping concerns

5. 05

   Faster titration is an unanswered benefit–toxicity trade-off, not a proven route to better clinical outcomes

6. 06

   Treatment-free periods are selective experiences, not a routine promise or evidence of cure

7. 07

   Hydroxyurea remains a credible choice; interferon preference is shaped by time horizon, patient priorities and specific constraints

8. 08

   Risk assessment and diagnostic work-up are treated as conditions for therapy, not as a single age or laboratory cutoff

9. 09

   Ruxolitinib is a symptom- and failure-driven alternative, with upfront positioning and long-exposure safety still questioned

10. 10

    Rusfertide is discussed chiefly as an adjunct or bridge, not as a substitute for anticlonal treatment

11. 11

    Patient expectations, access and research support are part of the treatment conversation

The full report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified claims with exact source passages.

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

2017-01-13 → 2026-09-14

Cited window

2017-01-13 → 2026-09-14

Retrieved

2026-10-08

Title

A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera

Registry

NCT01949805

Study IDs

PROUD-PV · 2012-005259-18

Sponsor

AOP Orphan Pharmaceuticals AG

Collaborators

PharmaEssentia (Co-Sponsor for USA)

Design

Phase 3 · interventional, randomized, parallel, phase3

Status

Completed

Enrollment

257 actual

Start

2013-09

Primary completion

2016-07 actual

Primary endpoint

Disease response rate

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
• –For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –22 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
• –13 further source limits are recorded in the machine-readable scope of this record.
• –Coverage is limited to the reviewed material. Some relevant recordings could not be accessed, and discussion using unnamed trial references or unfamiliar name variants may be absent.
• –Several sources contain the same conversation in different formats. Their repetition is not independent clinical corroboration, and source counts do not represent independent HCP counts.
• –Study outcomes, guideline descriptions, approval statements and dosing practices are generally reported by speakers. They remain attributed accounts rather than independently established trial results or prescribing guidance.
• –Some passages have incomplete sentences, uncertain measures or unclear clinical direction. The report does not supply a missing direction, threshold or referent.
• –Some speakers are identifiable only by a first name or remain unnamed. John, Toyosi and Tony are retained as established in their respective passages; a fuller identity is not inferred. Elissa Baldwin is retained as a host whose clinical role is unresolved in the supplied professional context.
• –Comments span different events and publication dates. The EHA22 debate was published in March 2023; later favorable posts or discussions do not establish a change of mind or disagreement across settings.
• –The supplied primary ancillary analysis was small and preliminary, and its clinical-outcome caveat belongs to that analysis’s period. It neither proves clinical benefit from molecular reduction nor negates later speaker-reported associations.

How reports are built and checked: Methods.

Last checked Oct 8, 2026. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch. No corrections.

release 7aa5a3fbfde5fc27a135d21399ccb79d14d11072ca035eef11595dc112da7630

The same record as JSON or Markdown, or through the Erudio MCP server.

curl https://www.erudio.com/reports/proud-pv-nct01949805.json
curl https://www.erudio.com/reports/proud-pv-nct01949805.md

# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "proud-pv-01949805" })